Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Malignant Melanoma

  Free Subscription


1 Am J Ophthalmol
3 Anticancer Res
1 Cancer Res
1 Cutis
2 Int J Cancer
1 J Biol Chem
1 J Clin Oncol
1 Lancet Oncol
1 Oncol Rep
1 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Ophthalmol

  1. FABIAN ID, Thaung C, AlHarby L, Sisley K, et al
    Late Solitary Extraocular Recurrence from Previously Resected Iris Melanoma.
    Am J Ophthalmol. 2017 Jun 30. pii: S0002-9394(17)30279.
    PubMed     Text format     Abstract available

    Anticancer Res

  2. USLU U, Schuler G, Breuninger H
    Factors Influencing Disease Progression in Patients with Head and Neck Melanoma.
    Anticancer Res. 2017;37:3811-3816.
    PubMed     Text format     Abstract available

  3. FURUDATE S, Fujimura T, Kambayashi Y, Kakizaki A, et al
    Immunomodulatory Effect of Imiquimod Through CCL22 Produced by Tumor-associated Macrophages in B16F10 Melanomas.
    Anticancer Res. 2017;37:3461-3471.
    PubMed     Text format     Abstract available

  4. NATH K, Nelson DS, Roman J, Putt ME, et al
    Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.
    Anticancer Res. 2017;37:3413-3421.
    PubMed     Text format     Abstract available

    Cancer Res

  5. Retraction: Molecular Mechanism of MART-1+/A*0201+ Human Melanoma Resistance to Specific CTL-Killing Despite Functional Tumor-CTL Interaction.
    Cancer Res. 2017;77:3718.
    PubMed     Text format    


  6. CERCI FB, Mesquita LA, Silva de Castro CC
    Segmental vitiligo-like hypopigmentation associated with metastatic melanoma.
    Cutis. 2017;99:E1-E2.
    PubMed     Text format    

    Int J Cancer

  7. KOU Y, Ji L, Wang H, Wang W, et al
    Connexin 43 Upregulation by Dioscin Inhibits Melanoma Progression via Suppressing Malignancy and Inducing M1 Polarization.
    Int J Cancer. 2017 Jul 5. doi: 10.1002/ijc.30872.
    PubMed     Text format     Abstract available

  8. BOTTERI E, Stoer NC, Sakshaug S, Graff-Iversen S, et al
    Menopausal hormone therapy and risk of melanoma: Do estrogens and progestins have a different role?
    Int J Cancer. 2017 Jul 7. doi: 10.1002/ijc.30878.
    PubMed     Text format     Abstract available

    J Biol Chem

  9. ZHAO L, Fan J, Xia S, Pan Y, et al
    HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers.
    J Biol Chem. 2017;292:10142-10152.
    PubMed     Text format     Abstract available

    J Clin Oncol

  10. LARKIN J, Minor D, D'Angelo S, Neyns B, et al
    Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
    J Clin Oncol. 2017 Jul 3:JCO2016718023. doi: 10.1200/JCO.2016.71.8023.
    PubMed     Text format     Abstract available

    Lancet Oncol

  11. FORSYTH PA, Smalley KSM, Sondak VK
    BRAF-MEK inhibition in melanoma brain metastases: a new hope.
    Lancet Oncol. 2017;18:836-837.
    PubMed     Text format    

    Oncol Rep

  12. FENG R, Gong J, Wu L, Wang L, et al
    MAPK and Hippo signaling pathways crosstalk via the RAF-1/MST-2 interaction in malignant melanoma.
    Oncol Rep. 2017 Jun 30. doi: 10.3892/or.2017.5774.
    PubMed     Text format     Abstract available

    PLoS One

  13. WANG S, Fan W, Wan B, Tu M, et al
    Correction: Characterization of long noncoding RNA and messenger RNA signatures in melanoma tumorigenesis and metastasis.
    PLoS One. 2017;12:e0181129.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  14. LUNAVAT TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, et al
    BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Proc Natl Acad Sci U S A. 2017 Jul 6. pii: 201705206.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.